Hepatic solitary fibrous tumor

Last revised by Dr Jeremy Jones on 20 Sep 2021

Hepatic solitary fibrous tumors (hepatic SFTs) are rare mesenchymal tumors.

Fewer than 60 cases have been reported in the literature. Female predominance (~70%). There is a mean age of 52 years at presentation, but a wide range of incidence (16-84 years).

If the patient is symptomatic at all, the presentation is usually mild and nonspecific, including abdominal pain, bloating, dyspepsia.

Hypoglycemia has been reported in some patients, presumably a paraneoplastic syndrome.

These tumors demonstrate high cellular proliferation of spindle cells arranged in a storiform pattern.

  • CD34: positive
  • vimentin: positive
  • Bcl-2: positive
  • SM-actin: negative

A prospective diagnosis of hepatic SFT is not usually possible because imaging features are usually relatively nonspecific. Intratumoral necrosis has been reported in a few lesions. Benign tumors cannot currently be reliably be differentiated from malignant tumors. 

  • nonspecific enhancing mass
    • heterogeneous enhancement has been reported
  • T1: hypointense
  • T2: heterogeneous appearance
  • T1 C+ (Gd): heterogeneous enhancement, depending on the relative amounts of cellular and collagen components
  • FDG-PET: avid FDG uptake 5

Most recorded hepatic SFTs are benign, but it is possible for them to exhibit malignant behavior 2. Some think that malignant foci may exist in biopsy-benign tumors, and the risk of malignancy is estimated at ~10% 1.

Given the rarity of the tumor, no standard treatment exists. Partial hepatectomy has been performed for some lesions, given the concern for occult malignancy.

ADVERTISEMENT: Supporters see fewer/no ads

Cases and figures

  • Case 1: axial bSSFP FS
    Drag here to reorder.
  • Updating… Please wait.

     Unable to process the form. Check for errors and try again.

     Thank you for updating your details.